Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Integrating injectable opioid agonist treatment into a drug treatment court program: A case study.

Jun JH, Fairbairn N.

Subst Abus. 2018;39(4):493-496. doi: 10.1080/08897077.2018.1485129. Epub 2018 Oct 2.

2.

Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.

Bansback N, Guh D, Oviedo-Joekes E, Brissette S, Harrison S, Janmohamed A, Krausz M, MacDonald S, Marsh DC, Schechter MT, Anis AH.

Addiction. 2018 Jul;113(7):1264-1273. doi: 10.1111/add.14171. Epub 2018 Mar 28.

PMID:
29589873
3.

Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.

Marchand KI, Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Schechter MT.

BMC Health Serv Res. 2011 Jul 26;11:174. doi: 10.1186/1472-6963-11-174.

4.

Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.

Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, Marsh DC, Schechter MT.

JAMA Psychiatry. 2016 May 1;73(5):447-55. doi: 10.1001/jamapsychiatry.2016.0109.

PMID:
27049826
5.

Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.

Palis H, Marchand K, Guh D, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT, Oviedo-Joekes E.

Subst Abuse Treat Prev Policy. 2017 May 19;12(1):25. doi: 10.1186/s13011-017-0110-9.

6.

Diacetylmorphine versus methadone for the treatment of opioid addiction.

Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT.

N Engl J Med. 2009 Aug 20;361(8):777-86. doi: 10.1056/NEJMoa0810635.

7.

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment.

Oviedo-Joekes E, Guh D, Marchand K, Marsh DC, Lock K, Brissette S, Anis AH, Schechter MT.

Subst Abuse Treat Prev Policy. 2014 Jun 8;9:23. doi: 10.1186/1747-597X-9-23.

8.

Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.

Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, Harrison S, Janmohamed A, Zhang DZ, Anis AH, Krausz M, Marsh DC, Schechter MT.

Drug Alcohol Depend. 2017 Jul 1;176:55-62. doi: 10.1016/j.drugalcdep.2017.02.021. Epub 2017 May 10.

PMID:
28521199
9.

Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.

Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B.

PLoS Med. 2019 Dec 31;16(12):e1003002. doi: 10.1371/journal.pmed.1003002. eCollection 2019 Dec.

10.

Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.

Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, Anis A, Schechter MT.

J Subst Abuse Treat. 2010 Jun;38(4):408-11. doi: 10.1016/j.jsat.2010.03.003. Epub 2010 Mar 31.

PMID:
20359843
11.

Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT).

Metrebian N, Groshkova T, Hellier J, Charles V, Martin A, Forzisi L, Lintzeris N, Zador D, Williams H, Carnwath T, Mayet S, Strang J.

Addiction. 2015 Mar;110(3):479-90. doi: 10.1111/add.12748. Epub 2014 Nov 7.

PMID:
25251885
12.

Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.

Bozinoff N, DeBeck K, Milloy MJ, Nosova E, Fairbairn N, Wood E, Hayashi K.

Drug Alcohol Depend. 2018 Dec 1;193:42-47. doi: 10.1016/j.drugalcdep.2018.09.003. Epub 2018 Oct 6.

13.

The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency.

Oviedo-Joekes E, Marchand K, Lock K, MacDonald S, Guh D, Schechter MT.

Subst Abuse Treat Prev Policy. 2015 Jan 26;10:3. doi: 10.1186/1747-597X-10-3.

14.

Successful treatment with slow-release oral morphine following afentanyl-related overdose: A case report.

Prinsloo G, Ahamad K, SocĂ­as ME.

Subst Abus. 2019;40(4):473-475. doi: 10.1080/08897077.2019.1576086. Epub 2019 Mar 4.

PMID:
30829174
15.

Supervised Injectable Opioid Treatment for the Management of Opioid Dependence.

Bell J, Belackova V, Lintzeris N.

Drugs. 2018 Sep;78(13):1339-1352. doi: 10.1007/s40265-018-0962-y. Review.

PMID:
30132259
16.

Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.

Dematteis M, Auriacombe M, D'Agnone O, Somaini L, Szerman N, Littlewood R, Alam F, Alho H, Benyamina A, Bobes J, Daulouede JP, Leonardi C, Maremmani I, Torrens M, Walcher S, Soyka M.

Expert Opin Pharmacother. 2017 Dec;18(18):1987-1999. doi: 10.1080/14656566.2017.1409722. Epub 2017 Dec 3. Review.

PMID:
29183228
17.

Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.

Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT.

Drug Alcohol Rev. 2018 Jan;37(1):137-146. doi: 10.1111/dar.12573. Epub 2017 Jun 8.

PMID:
28593748
18.

Controlled trial of prescribed heroin in the treatment of opioid addiction.

March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F; PEPSA team.

J Subst Abuse Treat. 2006 Sep;31(2):203-11. Epub 2006 Jul 18.

PMID:
16919749
19.

Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence.

Oviedo-Joekes E, Sordo L, Guh D, Marsh DC, Lock K, Brissette S, Anis AH, Schechter MT.

Addict Behav. 2015 Feb;41:81-6. doi: 10.1016/j.addbeh.2014.10.003. Epub 2014 Oct 7.

20.

The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.

Krebs E, Urada D, Evans E, Huang D, Hser YI, Nosyk B.

Addiction. 2017 May;112(5):838-851. doi: 10.1111/add.13729. Epub 2017 Feb 6.

Supplemental Content

Support Center